Brokerages Set Amgen Inc. (NASDAQ:AMGN) Target Price at $339.45

Amgen Inc. (NASDAQ:AMGN) has earned a consensus rating of “Moderate Buy” from the twenty-three brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $339.2381.

A number of research firms have commented on AMGN. Deutsche Bank Aktiengesellschaft raised their target price on Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a report on Tuesday, November 11th. Daiwa Capital Markets raised their price objective on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a research note on Tuesday, November 18th. UBS Group upgraded shares of Amgen to a “strong-buy” rating in a research report on Wednesday, January 7th. BMO Capital Markets increased their target price on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Finally, Cantor Fitzgerald boosted their price target on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Board-approved dividend increase to $2.52, boosting income appeal for dividend investors and supporting demand for the stock. Amgen Announces Dividend Increase
• Positive Sentiment: Amgen expanded its obesity strategy via a collaboration with Ro on GLP?1 therapies, strengthening its pipeline in high-growth metabolic indications and offering longer-term revenue upside. Amgen Expands Obesity Strategy with Ro Collaboration
• Positive Sentiment: Market momentum: AMGN reached a 52-week high, reflecting strong investor appetite tied to the dividend, pipeline news and overall biotech interest. Amgen Stock Hits 52-Week High
• Positive Sentiment: Analyst/investor bullishness on pipeline: a recent piece highlights MariTide’s obesity/T2D potential as a longer-term growth driver, supporting a constructive buy thesis for 2026+ revenue expansion. Amgen: A Buy In 2026 On MariTide Potential
• Neutral Sentiment: Near-term outlook: coverage noting upcoming earnings and pipeline catalysts — solid fundamentals but investors remain cautious ahead of quarterly reporting. Amgen Stock Outlook and Near-Term Earnings Focus
• Neutral Sentiment: Inclusion in dividend-focused lists (e.g., Dogs of the Dow coverage) underscores income-investor interest but is unlikely to move fundamentals materially. Dogs of the Dow Coverage
• Negative Sentiment: Litigation risk: Sagebrush has sued Amgen over practices related to the 340B program — a regulatory/legal dispute that could create reputational risk, potential fines or contract changes if escalated. Sagebrush Sues Amgen Over 340B Program
• Negative Sentiment: Follow-up coverage analyzing the Sagebrush suit highlights stakeholder friction around 340B — amplifies near-term headline risk that could pressure sentiment if litigation intensifies. Amgen Faces 340B Lawsuit Analysis
• Negative Sentiment: Analyst downgrade: Sanford C. Bernstein lowered AMGN to a Hold, and coverage notes a reduced rating — this can weigh on near-term sentiment despite strong earnings/guidance. Bernstein Downgrades Amgen to Hold

Amgen Price Performance

Shares of AMGN opened at $347.07 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The stock’s 50 day moving average is $331.91 and its two-hundred day moving average is $307.18. Amgen has a twelve month low of $261.43 and a twelve month high of $349.98. The firm has a market capitalization of $186.89 billion, a PE ratio of 26.82, a P/E/G ratio of 3.06 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The business had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. During the same period last year, the firm earned $5.58 EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Research analysts anticipate that Amgen will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Insider Activity

In other news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 over the last 90 days. 0.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. West Family Investments Inc. raised its holdings in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC increased its position in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock worth $2,023,000 after purchasing an additional 30 shares in the last quarter. LOM Asset Management Ltd raised its stake in Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares during the last quarter. Sittner & Nelson LLC lifted its holdings in Amgen by 0.4% in the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock valued at $2,053,000 after purchasing an additional 30 shares in the last quarter. Finally, ORG Partners LLC boosted its stake in shares of Amgen by 0.6% during the 4th quarter. ORG Partners LLC now owns 5,398 shares of the medical research company’s stock worth $1,767,000 after purchasing an additional 31 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.